ClinicalTrials.gg
Not yet recruitingNCT07845240BT-PPHUpdated Sep 28, 2026

Efficacy of Balloon Tamponade in Post-partum Hemorrhage Within 24 Hours After Delivery

An observational study in Postpartum Hemorrhage, sponsored by Aziz Fatimah Medical & Dental College, Faisalabad. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Aziz Fatimah Medical & Dental College, Faisalabad · Observational

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
121
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Postpartum Hemorrhage with a site in Pakistan — 4 open to participants now, 4 under way, none of them phase 3. Postpartum Hemorrhage · Pakistan.

Started
2026
with 2 others
Observational
Only one
of the 17
Registered
17th of 17
by date
Lead sponsor
1 of 17
Aziz Fatimah Medical & Dental College, Faisalabad

Among the 17 studies in Postpartum Hemorrhage with a site in Pakistan, this one is one of 3 that started in 2026, is the only observational one, and was the 17th registered.

Postpartum Hemorrhage

470 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

4 of the 17 studies in Postpartum Hemorrhage with a site in Pakistan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Postpartum Hemorrhage with a site in Pakistan, or all of them as a file.
02

Study summary

Postpartum hemorrhage (PPH) is a major cause of maternal death, especially in developing countries like Pakistan where it accounts for up to 34% of maternal deaths. When bleeding after delivery does not stop with medicines like oxytocin and uterine massage, a low-cost method called balloon tamponade can be life-saving.

This study titled "Efficacy of Balloon Tamponade in Post-partum Hemorrhage within 24 Hours After Delivery" will be conducted by Dr. Maryam Aslam (PGR Gynecology and Obstetrics) under supervision of Prof. Dr. Raheela Farhat at Aziz Fatima Hospital, Faisalabad.

The objective is to determine the efficacy of intrauterine balloon tamponade (condom catheter balloon) in controlling primary PPH. Efficacy is defined as successful control of bleeding within six hours of balloon insertion without need for additional surgery, confirmed by absence of active vaginal bleeding, a contracted uterine fundus, and stable maternal condition after removal of the balloon. The results will help promote a simple, effective procedure that can even be used by primary health care workers to reduce maternal mortality.

Read the detailed description

This is a Descriptive Cross-Sectional Study.

Title: Efficacy of Balloon Tamponade in Post-partum Hemorrhage within 24 hours after delivery.

Setting: Department of Obstetrics and Gynecology, Aziz Fatima Hospital, Faisalabad.

Duration: Six months after approval from CPSP. Sample Size: 121 patients, calculated by WHO sample size calculator using anticipated proportion 81%, significance level 5%, margin of error 7%.

Sampling Technique: Consecutive non-probability sampling.

Operational Definitions:

  1. Postpartum Haemorrhage (PPH): Blood loss of more than 500 ml (one kidney tray) following vaginal delivery and 1000 ml following cesarean section within 24 hours. Estimation by kidney tray method.
  2. Efficacy: Successful control of PPH within six hours of balloon insertion, without need for additional surgical intervention. Success is confirmed by absence of active vaginal bleeding, contracted uterine fundus, and stable maternal condition following gradual deflation and removal of the balloon device.

Inclusion Criteria:

  • Age 18-35 years
  • Gestational age between 31 to 41 weeks
  • Having primary PPH

Exclusion Criteria:

  • Obstetric hemorrhage (Antepartum Hemorrhage) \<31 weeks of gestation
  • Multiparity (Children more than 5)
  • Traumatic PPH (cervical and vaginal tears)
  • Allergy to latex
  • Acute uterine infection (chorioamnionitis)
  • Cases with bleeding disorders, ruptured uterus
  • Patient whose PPH is managed successfully with uterine curettage

Data Collection Procedure:

After approval from Institutional Ethical Committee (Ref: IEC/392-25 dated 30/09/2025) and CPSP, and informed consent from patients. Patients meeting inclusion criteria will be selected. A proforma will be used to document demographic data. Women with PPH who do not improve with uterotonics will be evaluated for treatment with condom and Foley catheter balloon. A condom-lined sterile rubber catheter will be inserted into the uterus under strict aseptic technique. The balloon will be placed on cervix and held with roller gauze and sponge-holding forceps. 300-400 ml of regular normal saline will be used to inflate the condom. The catheter condom will be stored for up to six hours. If no active bleeding is detected through the cervix and uterine fundus is felt contracted after 6 hours, balloon will be slowly deflated at rate of 50 ml/hour to half its volume in 2 hours. If no further bleeding occurs during next 30 minutes, balloon will be removed in presence of senior staff member. If bleeding persists or uterine fundus rises, condom tamponade will be abandoned and surgical intervention will be pursued.

Data Analysis:

Data will be entered into SPSS version 25. Mean and standard deviation will be calculated for quantitative variables such as age, gestational age, blood loss. Frequencies and percentages will be used for categorical variables such as socioeconomic status, education status, booking status, parity, mode of delivery and efficacy. Chi-square test will be applied to efficacy. Effect modifiers like age, gestational age, blood loss, socioeconomic status, education status, booking status, parity, mode of delivery will be controlled by stratification. Post-stratification chi-square test will be applied and P-value \<0.05 will be considered statistically significant.

03

Conditions studied

  • Postpartum Hemorrhage

Browse trials for

Keywords

  • Balloon Tamponade
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18-35 years with gestational age 31-41 weeks presenting with primary postpartum hemorrhage unresponsive to medical management at Department of Obstetrics and Gynaecology, Allied Hospital Faisalabad. Total 121 participants selected via consecutive non-probability sampling as per WHO sample size calculator with 7% margin of error.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years
  • Having gestational age between 31 to 41 weeks
  • Having PPH (Primary postpartum hemorrhage unresponsive to uterotonics)

Exclusion criteria

Exclusion Criteria:

  • Patient who has Obstetric hemorrhage (Antepartum Hemorrhage) \<31 weeks of gestation
  • Multiparity (Children more than 5)
  • Traumatic PPH (cervical and vaginal tears)
  • Allergy to latex
  • Acute uterine infection (chorioamnionitis)
  • Cases with bleeding disorders, ruptured uterus
  • Patient whose postpartum hemorrhage is managed successfully with uterine curettage
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
121 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • This cohort includes 121 women aged 18-35 years with gestational age 31-41 weeks who developed prima

    A condom-lined sterile rubber catheter will be inserted into the uterus under strict aseptic conditions. Balloon placed on cervix and held with roller gauze and sponge-holding forceps. Balloon inflated with 300-400 ml of regular normal saline and kept for up to six hours. If no active bleeding detected through cervix and uterine fundus felt contracted after 6 hours, balloon will be slowly deflated at rate of 50 ml/hour to half its volume in 2 hours. If no further bleeding during next 30 minutes, balloon removed in presence of senior staff. If bleeding persists or fundus rises, tamponade abandoned and surgical intervention pursued. Efficacy defined as successful control of PPH within six hours of insertion without need for additional surgery, confirmed by absence of active vaginal bleeding, contracted uterine fundus and stable maternal condition.

    Device: Intrauterine Balloon Tamponade - Condom Catheter

Interventions

  • DeviceIntrauterine Balloon Tamponade - Condom Catheter

    Condom-lined sterile rubber catheter inserted into uterus under aseptic technique, held with roller gauze and sponge-holding forceps. Balloon inflated with 300-400 ml normal saline and kept up to 6 hours. If no active bleeding and uterine fundus contracted after 6 hours, balloon deflated at 50 ml/hour to half volume in 2 hours then removed if no bleeding in next 30 min in presence of senior staff. If bleeding persists, tamponade abandoned and surgical intervention pursued. Efficacy is successful control of PPH within 6 hours without additional surgery, confirmed by absence of active vaginal bleeding, contracted fundus and stable maternal condition.

06

What researchers measure

Primary outcomes

  1. Efficacy of intrauterine condom catheter balloon tamponade in control of primary postpartum hemorrhage

    Efficacy is defined as successful control of primary PPH within 6 hours of balloon insertion without need for additional surgical intervention. Success confirmed by absence of active vaginal bleeding, contracted uterine fundus on abdominal palpation and stable maternal vital signs and general condition. Failure defined as persistent bleeding or rising fundus requiring surgical intervention.

    Time frame: Within 6 hours of intervention and assessed for 30 minutes after deflation

07

Study locations

1 site
  • Aziz Fatima hospital
    Faisalābad, Punjab Province 38000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional ethical restrictions and confidentiality of this academic dissertation project at Aziz Fatimah Hospital Faisalabad.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845240
Lead sponsor
Aziz Fatimah Medical & Dental College, Faisalabad
Responsible party
maryam aslam (Postgraduate Resident, Obstetrics & Gynaecology, Aziz Fatimah Medical & Dental College, Faisalabad) — Principal investigator
First posted
Sep 28, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Maryam Aslam, MBBS
Contact
aslammaryam18@gmail.com
03038059729

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion